GET THE APP

..

Pulmonary & Respiratory Medicine

ISSN: 2161-105X

Open Access

Citations Report

Pulmonary & Respiratory Medicine : Citations & Metrics Report

Articles published in Pulmonary & Respiratory Medicine have been cited by esteemed scholars and scientists all around the world.

Pulmonary & Respiratory Medicine has got h-index 20, which means every article in Pulmonary & Respiratory Medicine has got 20 average citations.

Following are the list of articles that have cited the articles published in Pulmonary & Respiratory Medicine.

  2024 2023 2021 2020 2019 2018

Total published articles

40 49 60 28 19 41

Research, Review articles and Editorials

3 1 0 0 0 0

Research communications, Review communications, Editorial communications, Case reports and Commentary

37 48 0 0 0 0

Conference proceedings

0 0 16 0 11 57

Citations received as per Google Scholar, other indexing platforms and portals

1784 1347 168 194 193 169
Journal total citations count 1690
Journal impact factor 1.80
Journal 5 years impact factor 2.06
Journal cite score 6.21
Journal h-index 20
Journal h-index since 2019 15
Important citations

Matera MG, Ora J, Cazzola M (2015) Differential pharmacology and clinical utility of long-acting bronchodilators in COPD–focus on olodaterol. Therapeutics and clinical risk management 11: 1805.

Melani AS (2015) Long-acting muscarinic antagonists. Expert review of clinical pharmacology 8: 479-501.

Joos GF, Aumann JL, Coeck C, Korducki L, Hamilton AL, et al. (2015) A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV 1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β 2-agonist, in patients with chronic obstructive pulmonary disease. Respiratory medicine. 109: 606-615.

Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, et al. (2015) Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat® Inhaler in patients with chronic obstructive pulmonary disease. Advances in therapy. 32: 809-822.

Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, et al. (2015) A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β 2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respiratory medicine. 109: 596-605.

Deeks ED (2015) Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 75: 665-673.

Disse B, Becker K (2014) Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. International Journal of COPD 9: 813-824.

Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, et al. (2015) The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulmonary pharmacology & therapeutics. 32: 53-59.

Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, et al. (2015) Tiotropium+ olodaterol shows clinically meaningful improvements in quality of life. Respiratory medicine. 109: 1312-1329.

Zamora-Chávez A, Sadowinski-Pine S, Serrano-Bello C, Velázquez-Jones L, Saucedo-Ramírez OJ, et al. (2016) Sarcoidosis en la infancia. Una rara enfermedad sistémica. Boletín Médico del Hospital Infantil de México. 73: 117-128.

Raspanti GA. LUNG CANCER IN NEPAL: THE ROLE OF TRADITIONAL TOBACCO PRODUCTS AND COMBUSTION RELATED HOUSEHOLD AIR POLLUTION (Doctoral dissertation).

KuršvietienÄ— L, StanevičienÄ— I. AKTYVIŲJŲ DEGUONIES FORMŲ IR ANTIOKSIDANTŲ POVEIKIS BIOMOLEKULÄ–MS IR REIKŠMÄ– LIGŲ PATOGENEZÄ–JE. Redaktorių taryba.:9.

Janssen WJ, Nozik-Grayck E. Power of Place: Intravascular Superoxide Dismutase for Prevention of Acute Respiratory Distress Syndrome.

Lunguleac T, Balmus IM, Grigorescu C. OXIDATIVE STRESS IMPLICATIONS IN VARIOUS LUNG DISEASES. FOCUSING ON ONE LUNG VENTILATION.

Applying biotechnology and bioengineering to pediatric lung disease: emerging paradigms and platforms

Dingemanse J, Bolli M, Iglarz M (2015) Treatment of obesity and pulmonary arterial hypertension with inhibitors of the prostaglandin transporter: evaluation of patent WO2014/204895A1. Expert opinion on therapeutic patents 25: 1069-1077.

Feher A, Sinusas AJ. Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension.

Kim HJ, Yoo HY (2016) Hypoxic pulmonary vasoconstriction and vascular contractility in monocrotaline-induced pulmonary arterial hypertensive rats. The Korean Journal of Physiology & Pharmacology 20: 641-647.

Karch SB, Vaiano F, Bertol E (2015) Levamisole, Aminorex, and Pulmonary Arterial Hypertension: A Review. Razavi International Journal of Medicine: 3.

BellÃ?Æ?Ã?³-Klein A, Araujo AS, Schenkel PC, de Lima Seolin BG (2016) Oxidative Stress Influence in the Development of Pulmonary Arterial Hypertension. InBiochemistry of Oxidative Stress. Springer International Publishing: 213-226.

Google Scholar citation report
Citations: 1690

Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report

Pulmonary & Respiratory Medicine peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward